Search Results
Your search for ,CNS matches 885 pages
Showing 701 - 750MSH6 Mutations May Influence Temozolomide Resistance in Treatment-Naive Gliomas Independent of MGMT Methylation
Resistance to temozolomide in glioblastoma has been thought to be largely mediated by expression of the DNA repair enzyme MGMT, although there are data suggesting a role for inactivation of MSH6 and other mismatch repair proteins. In a study reported in Clinical Cancer Research, Nguyen and...
Dissemination of Glioblastoma Multiforme Outside Brain Is Common
The finding of extracranial metastases after organ transplantation from glioblastoma multiforme donors raised issues with the notion that disease spread is restricted to the brain. In a study reported in Science Translational Medicine, Müller and colleagues found that hematogenous spread of...
2014 Oncology Meetings
OCTOBER 18th SIS World Congress on Breast HealthcareOctober 16-19 • Orlando, Florida For more information: www2.kenes.com/sis/Pages/Home.aspx 2014 Quality Care SymposiumOctober 17-18 • Boston, MassachusettsFor more information: quality.asco.org Atlanta Lung Cancer SymposiumOctober 18 • Atlanta,...
Failure of Cilengitide in Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
Temozolomide in combination with radiation for newly diagnosed glioblastoma was approved by the U.S. Food and Drug Administration in 2005—almost 10 years ago—but we have unfortunately made little progress in improving survival for this incurable brain tumor. Despite recent completion of three...
CENTRIC Trial Shows No Benefit of Adding Cilengitide to Therapy in Glioblastoma With Methylated MGMT Promoter
In the phase III CENTRIC/European Organisation for Research and Treatment of Cancer (EORTC) 26071-22072 trial reported in The Lancet Oncology, Roger Stupp, MD, of University Hospital Zurich, and colleagues found that adding the selective αvβ3 and αvβ5 integrin inhibitor cilengitide to standard...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to elicit ...
2014 Oncology Meetings
NOVEMBER Chemotherapy Foundation SymposiumNovember 4 - 8 • New York, New YorkFor more information:www.chemotherapyfoundationsymp-osium.org Diagnostic Error in Medicine 5th International ConferenceNovember 11-14 • Baltimore, MarylandFor more information:www.hopkinscme.edu/CourseDetail.aspx/80028747...
MD Anderson Receives $5 Million Grant for Research in Glioblastoma
The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center in Houston. James and Jamie Broach established the Broach Foundation in 2011, just months after Mr. Broach was diagnosed...
Effect of Micro-RNA on M2 Macrophages and Murine Glioblastoma
Monocyte-derived glioma-associated macrophages are the largest infiltrating immune cell population in glioblastomas and act to facilitate gliomagenesis. In a study reported in the Journal of the National Cancer Institute, Xu and colleagues assessed the effect of microRNA (miR)-142-3p on...
A Candidly Humorous Approach to the Cancer Journey
BOOKMARK Title: Shrinkage: Manhood, Marriage, and the Tumor That Tried to Kill MeAuthor: Bryan BishopPublisher: Thomas Dunne BooksPublication date: April 29, 2014Price: $25.99; hardcover, 336 pages At 30 years old, Bryan Bishop was having the time of his life. Known to millions of radio fans as...
Whole-Brain Radiation Therapy Plus Stereotactic Radiosurgery Improves Survival in Better-Prognosis Patients With Brain Metastases
In a secondary analysis utilizing the graded prognostic assessment—an improved diagnosis-specific index—patients with one to three brain metastases had no survival advantage when treated with whole-brain radiation therapy and stereotactic radiosurgery, compared with whole-brain radiotherapy alone,...
Bevacizumab Plus Chemotherapy in Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 14, 2014, bevacizumab (Avastin) in combination with...
Treating Brain Cancer in 2014
While primary malignant brain tumors account for only 2% of all adult cancers, these deadly neoplasms cause severe cancer-related disability; the 5-year survival rates for brain tumors rank third lowest among all cancers, with those for pancreas and lung cancers being first and second lowest,...
Top 5 Breakthroughs in the Treatment of Advanced Lung Cancer
A countdown of the top 5 breakthrough therapies in the treatment of advanced lung cancer was presented by D. Ross Camidge, MD, PhD, at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.1 Dr. Camidge is Director, Thoracic Oncology Clinical and Clinical Research Programs, and...
Ten Best-Practice Measures Improve Quality of Care During Perioperative Period for Patients With Glioma
Ten best-practice measures identified by a multidisciplinary team at the Norris Cotton Cancer Center (NCCC) at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, were used to improve the care provided to patients with glioma during the perioperative period. “Using a plan-do-study-act ...
Clinical Trials Actively Recruiting Patients With Glioblastoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with newly diagnosed or recurrent glioblastoma multiforme. The studies include pilot, phase I, I/II, III, and observational trials investigating chemoradiation therapy;...
Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy: A Winner in Older Patients With Leukemia
Inotuzumab ozogamicin combined with a low-intensity chemotherapy called mini-hyper-CVD achieved highly encouraging results in older patients with acute lymphoblastic leukemia (ALL) in a phase II study reported at the 56th Annual Meeting of the American Society of Hematology.1 After the...
Dr. Howard Fine Named Founding Director of the Brain Tumor Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Howard A. Fine, MD, has been appointed to lead the newly established neuro-oncology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, effective February 2. He will serve as Director of the Brain Tumor Center and Associate Director for Translational Research in the Sandra and...
Glioblastoma Clinical Trials
I am writing in regard to the recent installment to “Clinical Trials” on Glioblastoma published in The ASCO Post (February 10, 2015, pages 69-71). As a principal investigator, I’d also like to call attention to the following glioblastoma trial, which remains open. PHASE II Study Type: Phase...
Having Cancer So Early in Life Gave Me Purpose
I had every classic brain tumor symptom in the book—severe headaches, dizziness, morning nausea—which plagued me for 16 years, starting when I was 8. In college, if I allowed myself to sleep more than 4 hours a night, the morning headaches, which were centered on the top of my head, were so severe, ...
Dinutuximab Combination Approved for Pediatric High-Risk Neuroblastoma
The U.S. Food and Drug Administration (FDA) has approved dinutuximab (Unituxin), a monoclonal antibody targeting glycolipid GD2, as part of first-line therapy for pediatric patients with high-risk neuroblastoma. A chimeric monoclonal antibody that binds to the surface of neuroblastoma cells,...
Dinutuximab in Pediatric High-Risk Neuroblastoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 10, 2015, the chimeric monoclonal antibody dinutuximab...
Clinical Trials Actively Recruiting Patients With Neuroblastoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with newly diagnosed or relapsed or refractory neuroblastoma. The studies include pilot, observational, phase I, phase II, and phase III trials investigating single-agent and...
EGFR Amplification/Overexpression Associated With Improved Response of Glioblastoma to Metronomic Temozolomide
In a study reported in Journal of the National Cancer Institute, Cominelli and colleagues found that EGFR amplification/overexpression was associated with improved response of glioblastoma to adjuvant metronomic (every day of a 28 day cycle at a dosing of 50-75 mg/m2) but not standard (5...
The Paradox of Positive Thinking
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?
Although the idea of using viruses to target cancer cells dates back more than 100 years, technologic advances in the genetic engineering of viruses are now making it possible to safely test oncolytic virotherapy as a valid strategy against cancer cells. One type of genetically engineered virus...
Whole-Brain Radiation: Risks Outweigh Benefits for Limited Brain Metastases
New data from a phase III Alliance trial weighs in on a longstanding debate in the treatment of brain metastases: Should whole-brain radiation therapy be added to stereotactic radiosurgery? The study found that although whole-brain radiation therapy improved local tumor control in patients with...
Poliovirus for Glioblastoma Grabs National Attention
Researchers at The Preston Robert Tisch Brain Tumor Center at Duke University are being barraged by patients wishing to enroll in their clinical trial of an engineered poliovirus for recurrent glioblastoma. This comes as a result of a CBS 60 Minutes interview with lead researcher Matthias...
Investigators Update PVS-RIPO Data in Glioblastoma
At the 2015 ASCO Annual Meeting, Annick Desjardins, MD, Associate Professor of Neurology at Duke University Medical Center, presented a brief update on the ongoing study of oncolytic PVS-RIPO in glioblastoma, which now includes 24 patients.1 The median age of enrolled patients is 57, most have a...
New Concept for Brain Tumors: Tumor Treating Fields
A novel treatment modality that applies electric forces to brain tumors via scalp electrodes improved outcomes in a study reported at the 2015 ASCO Annual Meeting.1 In the first report of the full dataset, tumor treating fields significantly and consistently prolonged both progression-free...
FDA Grants Orphan Drug Designation to Antitropomyosin Drug for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Novogen Limited’s chemotherapy candidate drug Anisina for neuroblastoma. Anisina is a small molecule belonging to a family of compounds called antitropomyosins. It has been designed to inhibit Tpm3.1, a structural...
Glioblastoma: Novel Immunotherapy Approaches Generate Responses and Excitement
Checkpoint inhibitors were major attention grabbers at the 2015 ASCO Annual Meeting, but studies suggested there are other encouraging means of harnessing the immune system in the treatment of glioblastoma. EGFRvIII-Targeted Vaccine David A. Reardon, MD, Clinical Director of the Center for...
Improved Understanding of Glioma Tumor Biology
The management of patients with lower-grade gliomas is evolving. As evidenced by two recent publications in The New England Journal of Medicine,1,2 reviewed in this issue of The ASCO Post, there has been a substantial increase in our knowledge of the molecular characteristics of these neoplasms....
New Molecular Classifications of Gliomas Established
Two studies reported in The New England Journal of Medicine identified new molecular classifications of glioma that capture biologic and prognostic differences. The Cancer Genome Atlas Research Network identified three prognostically significant subtypes of lower-grade glioma that were identified...
Short Course of Radiotherapy May Be Adequate for Elderly and Frail Patients With Glioblastoma Multiforme
No difference in overall survival or progression-free survival was observed between elderly and/or frail patients undergoing short and standard courses of radiotherapy for glioblastoma multiforme, according to data presented by Elena Fidarova, MD, at the 2015 Multinational Association of Supportive ...
Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Question 1: What is the most likely diagnosis for this patient? Correct Answer: B. Primary central nervous system lymphoma. Expert Perspective In an immunocompetent host, the differential diagnosis of isolated or multiple brain lesion(s) includes autoimmune etiologies such as neurosarcoidosis,...
California Agency Invests $20 Million in Clinical Trial for Glioblastoma Vaccine
California’s Stem Cell Agency (CIRM) has awarded $19.9 million to ImmunoCellular Therapeutics to carry out a phase III clinical trial in patients with newly diagnosed glioblastoma using an immunotherapeutic vaccine. “This kind of deadly disease is precisely why we created CIRM 2.0, our new...
FDA Approves Expanded Indication for Medical Device to Treat Newly Diagnosed Glioblastoma Multiforme
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for the Optune tumor-treating fields device to treat patients with newly diagnosed glioblastoma multiforme. It is given along with the chemotherapy drug temozolomide following standard treatments that include surgery,...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to elicit ...
Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Question 1: What is next best step in the management of this patient? Correct Answer: C. Ophthalmoscopy/slit lamp examination. Expert Perspective Ophthalmic involvement should be sought by noninvasive procedures such as slit lamp examination and ophthalmoscopy and abnormal findings must be...
Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear here with expert commentary. In the October 25 issue of The ASCO Post, part 1 of a...
Cooperative Group Study Finds Radiation May Benefit Patients With Atypical Meningiomas
Management of the vast majority of meningiomas is straightforward, but treatment of atypical meningiomas has been controversial. Should radiation be part of therapy or not has been the question. The first analysis of Radiation Therapy Oncology Group (RTOG) 0539 suggested that patients will have...
Pilot Study: Research Team Used Focused Ultrasound to Open Blood-Brain Barrier in Patient With Malignant Brain Tumor
A team at Sunnybrook Health Sciences Centre in Toronto has used focused ultrasound to enable temporary and targeted opening of the blood-brain barrier, allowing the more effective delivery of chemotherapy into a patient’s malignant brain tumor. This is the first known report of the noninvasive...
Actionable Targets Identified in Brain Metastases
New research shows that paired primary tumor and brain metastases share a common ancestor, but as the metastases develop in the brain, they exhibit novel genetic alterations that can activate a number of signaling pathways. More than half of the mutations represent potential therapeutic targets....
Study Lowers the Age Bar for Radiation in Children With Ependymoma
The good news is that children as young as 1 year old with the aggressive brain tumor ependymoma can be treated safely and effectively with immediate postoperative radiation therapy, according to the results of a trial presented at the 2015 ASTRO Annual Meeting.1 “Ependymoma is the third most...
Third Annual JADPRO Live at APSHO Conference Attracts Over 700 Advanced Practitioners in Hematology-Oncology
Over 700 nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and other oncology health-care professionals were convened in Phoenix, Arizona, earlier this month to participate in JADPRO Live at APSHO (Advanced Practitioner Society in Hematology and Oncology), the...
A: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Question 1: Based on the rationale for the current “standard of care” for primary diffuse large B-cell lymphoma of the CNS, what is the optimal induction therapy? Correct Answer: C. A high-dose methotrexate–based regimen. Expert Perspective Untreated primary diffuse large B-cell lymphoma of the CNS ...
Q: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear on page 84 with expert commentary. In the November 10 issue of The ASCO Post, part 2 of ...
ASCO Endorsement of ACCP Guideline on Treating SCLC: Moving Forward to Better Outcomes in Oncology
In the current climate of rising health-care costs, particularly in the field of oncology, clinical guidelines provide a crucial tool to guide practitioners in evidence-based care and to improve the quality and consistency of care.1 The ASCO review and endorsement of the American College of Chest...
